Victory Capital Management Inc Cyma Bay Therapeutics, Inc. Transaction History

Victory Capital Management Inc

$95.8 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$12.63 - $24.47 $4.39 Million - $8.51 Million	-347,830 Reduced 33.53%	689,603 $16.3 Million
Q3 2023 Nov 06, 2023	BUY	$10.86 - $17.62 $10.7 Million - $17.4 Million	988,683 Added 2028.07%	1,037,433 $15.5 Million
Q2 2023 Jul 27, 2023	BUY	$7.47 - $10.95 $288,887 - $423,469	38,673 Added 383.77%	48,750 $533,000
Q1 2023 May 02, 2023	BUY	$5.88 - $9.59 $59,252 - $96,638	10,077 New	10,077 $87,000
Q4 2021 Feb 07, 2022	SELL	$3.23 - $4.6 $137,107 - $195,260	-42,448 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$3.94 - $4.92 $110,296 - $137,730	-27,994 Reduced 39.74%	42,448 $185,000
Q1 2021 May 04, 2021	SELL	$4.23 - $6.55 $11,729 - $18,163	-2,773 Reduced 3.79%	70,442 $320,000
Q4 2020 Feb 01, 2021	BUY	$5.73 - $9.03 $129,847 - $204,628	22,661 Added 44.83%	73,215 $420,000
Q3 2020 Nov 09, 2020	SELL	$3.32 - $7.24 $73,896 - $161,147	-22,258 Reduced 30.57%	50,554 $366,000
Q1 2020 May 04, 2020	SELL	$1.25 - $2.02 $5,207 - $8,415	-4,166 Reduced 5.41%	72,812 $108,000
Q4 2019 Feb 06, 2020	BUY	$1.33 - $5.93 $5,540 - $24,704	4,166 Added 5.72%	76,978 $151,000
Q4 2019 Feb 04, 2020	SELL	$1.33 - $5.93 $5,540 - $24,704	-4,166 Reduced 5.41%	72,812 $112,000
Q3 2019 Nov 12, 2019	BUY	$5.12 - $7.21 $387,584 - $545,797	75,700 Added 5923.32%	76,978 $394,000
Q4 2018 Feb 05, 2019	SELL	$6.54 - $11.74 $1,595 - $2,864	-244 Reduced 16.03%	1,278 $10,000
Q3 2018 Nov 01, 2018	BUY	$10.88 - $14.52 $2,176 - $2,904	200 Added 15.13%	1,522 $17,000
Q2 2018 Aug 02, 2018	BUY	$10.66 - $14.38 $14,092 - $19,010	1,322 New	1,322 $18,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Account